CHAGAS' DISEASE: IgA, IgM AND IgG ANTIBODIES TO T. cruzi AMASTIGOTE, TRYPOMASTIGOTE AND EPI mastigote ANTIGENS IN ACUTE AND IN DIFFERENT CHRONIC FORMS OF THE DISEASE

Katia S. C. PrimaVera (1), Eufrosina S. Umezawa (2), Benedito Anseime Peres (2), Mario E. Camargo (2) & Sumie HosHino-Shimizu (1)

SUMMARY

In an attempt to find a better T. cruzi antigen and possible immunological markers for the diagnosis of different clinical forms of Chagas' disease, amastigote and trypomastigote antigens obtained from immunosuppressed mice infected with T. cruzi (Y strain) were assessed in comparison with conventional epimastigote antigens. A total of 506 serum samples from patients with acute and with chronic (indeterminate, cardiac and digestive) forms, from nonchagasic infections, and from healthy individuals were assayed in immunofluorescence (IF) tests, to search for IgG, IgM and IgA antibodies. Amastigote proved to be the most convenient antigen for our purposes, providing higher relative efficiency indexes of 0.946, 0.871 and 0.914 for IgG, IgM and IgA IF tests, respectively. Anti-amastigote antibodies presented higher geometric mean titers (GMT) than anti-trypomastigote and anti-epimastigote. Anti-amastigote IgG antibodies were found in all forms of Chagas' disease, and predominantly IgA antibodies, in chronic digestive and in acute forms, as well as IgM antibodies, in latter forms. Thus, tests with amastigote antigen could be helpful for screening chagasic infections in blood banks. Practical and economical aspects in obtaining amastigotes as here described speak in favour of its use in developing countries, since those from other sources require more complex system of preparation, specialized personnel or equipment.

KEY WORDS: T. cruzi infections; IgG, IgM and IgA antibodies; Amastigote, Trypomastigote and Epimastigote.

INTRODUCTION

In areas in which Chagas' disease is endemic, the prevalence of chronic infections is high, and because of low parasitemia in such infections, the diagnosis is made mostly based on serological data. To the moment, T. cruzi epimastigote is utilized widely as antigen in conventional serological tests. In recent review on assessment of different trypanosome antigens for diagnostic purpose, the reports about epimastigote antigen exceeded strikingly in number (84%) over other

(1) Setor de Imunologia Clinica, Departamento de Analises Clinicas e Toxicologicas, Faculdade de Ciencias Farmaceuticas, Universidade de Sao Paulo, SP, Brazil.
(2) Instituto de Medicina Tropical de Sao Paulo, Sao Paulo, SP, Brazil.
parasite life cycle stage antigens, as tryptomastigote (9%) and amastigote (7%)\textsuperscript{14}. Some serological tests are also capable to provide certain information about the clinical forms of Chagas' disease, since a close positive correlation between the acute form and IgM anti-epimastigote was seen, as well as, the chronic digestive form and anti-amas tigote IgA antibodies\textsuperscript{13, 18}. Antigenic difference between life cycle stage of \textit{T. cruzi} are known\textsuperscript{19}, but tryptomastigote and amastigote from vertebrate host seem to be more sensitive and adequate for the study of humoral immune response in chagasic patients\textsuperscript{9, 10, 16} than axenic epimastigote.

However, a better comparative study of amastigote, tryptomastigote and epimastigote antigens for the diagnosis of chagasic infections was not done before. Therefore, this aspect was further explored here, as well as, an attempt to find other immunological markers for different forms of Chagas' disease (acute and chronic indeterminate, cardiac and digestive) was made, associating the findings on IgG, IgM and IgA antibodies with those clinical forms and with referred three life cycle stages of \textit{T. cruzi} antigens, in the immunofluorescence test.

**MATERIAL AND METHODS**

**Serum samples:** Serum samples were collected from 506 individuals, 225 of which had Chagas' disease, 121 of which had nonrelated infections or autoimmune disease, and 160 of which were clinically healthy. Chagasic patients included 36 with acute, 128 with chronic indeterminate, 31 with cardiac and 30 with digestive forms. All the acute infections were parasitologically confirmed by direct microscopic examinations of blood samples or xenodiagnosis. Chronic cases were classified according to clinical, electrocardiographic and radiological criteria. The indeterminate forms included patients with no clinical symptoms of the disease and a normal or only slightly abnormal electrocardiogram. The cardiac form patients had cardiomyopathy with cardiac insufficiency, cardiomegaly, and an abnormal electrocardiogram. The digestive forms included patients with radiographically detected digestive abnormalities. In 11 of the 30 cases in this group, cardiac disease was also present.

A total of 121 patients with non-related infections were studied: 10 with clinically active rubella; 20 with malaria with patent parasitemia; 19 with acute toxoplasmosis; 10 of different age groups and from areas not endemic for Chagas' disease with clinically active Kala-azar; 12 with mucocutaneous leishmaniasis; 10 with recent syphilis; 32 with connective tissue diseases, including 18 with antinuclear antibodies and 16 with high-titer rheumatoid factors, and 8 with \textit{Pemphigus foliaceus}. Of the clinically healthy individuals, 100 were selected in an endemic area for Chagas' disease, and 60 were blood bank donors. Negative serology (Complement fixation, IF and indirect hemagglutination (HA) tests) for Chagas' disease was seen in all non-chagasic individuals, except for a few of the patients with Kala-azar. Patients with other diseases had positive results for their respective serodiagnosis.

Serum samples were obtained from venous blood and kept at -20°C until use.

**Serological tests for Chagas' disease:** All sera were assessed in complement fixation, IF for IgG antibody (IgG IF) and indirect HA (IHA) tests for Chagas' disease as described previously\textsuperscript{4}. Serum samples from chagasic patients were also tested by an enzyme-linked immunosorbent assay for IgG antibodies\textsuperscript{29}. Also, IF for IgM antibody (IgM IF) and polysaccharide IHA tests were carried out to reveal IgM antibodies in acute cases\textsuperscript{13}. To avoid interference of rheumatoid factors in the IgM IF test, we pretreated the serum samples, which were positive in a rheumatoid factor latex agglutination test (Behringwerke A. G.), with aggregated human gamma-globulin\textsuperscript{51}. In the IF tests, the anti-IgA (\(\alpha\) chain specific), IgM (\(\mu\) chain specific) and IgG (\(\delta\) chain specific) fluorescent conjugate were used. All the IF test results were scored arbitrarily from 4+ to 1+ and doubtful or weak fluorescence considered as negative.

**Parasite antigens:** Parasite antigens were prepared from various \textit{T. cruzi} life cycle stages. Epimastigotes antigens were obtained as described previously\textsuperscript{6}. Blood stream tryptomastigotes were collected from immunosuppressed mice, inoculated with trypanosome, on day 7 post infection, as reported\textsuperscript{15}, and processed as for epimastigote\textsuperscript{6}. Intracellular amastigotes were ta-
ken from liver and spleen of infected mice, purified by two-step discontinuous gradient centrifugation as described previously and also processed as described for epimastigotes.

For the evaluation of each of studied antigens, diagnostic performance indexes were estimated in terms of relative sensitivity, specificity and efficiency according to GALLEN & GAMBINO and the cutoffs taken at their highest efficiency indexes. To calculate geometric mean titers (GMT) of IgG, IgM and IgA antibodies and standard deviations (sd), the titers (T) were transformed to log2 (log2 0.4T) according to WHITE.

RESULTS

Serum samples from chagasic patients were all reactive in the enzyme-linked immunosorbent assay and most were reactive in the three other conventional tests, IgG IF, IHA and complement fixation, or at least in two of these. The 36 serum samples from patients with acute Chagas' disease were reactive in both IgM IF and polysaccharide IHA tests, or in one of these, as well. Samples from patients with other diseases were non-reactive, except 2 cases of Kala-azar and 5 from healthy individuals, in which the titers were low (≤ 80).

To define possible immunological marker for different forms of Chagas'disease, as well as to verify the better antigen for diagnostic purpose, cutoff titers were established for each test to distinguish, with highest efficiency, each form of Chagas'disease from other forms of the same disease, other infections, and normal individuals. Group of patients with acute forms were studied independently from the group with chronic digestive forms in IgA IF test. For the study of former group, the latter was not included, and conversely, for the study of latter group, the former was excluded, since, although acute infections have IgA-reactive antibodies, they can be distinguished from patients with other Chagas' disease, because they have anti-T. cruzi IgM antibodies in their sera.

Table 1 indicates sensitivity, specificity, and efficiency indexes for selected cutoffs. In general, IF tests with amastigote antigens provided higher efficiency values, followed by tests with trypomastigote, except in IgM IF test.

TABLE 1
Diagnostic performance indexes of IF tests for IgG, IgM and IgA antibodies with T. cruzi amastigote, trypomastigote and epimastigote antigens in patients with acute and with chronic indeterminate, cardiac and digestive forms of Chagas'disease

<table>
<thead>
<tr>
<th>IF Test</th>
<th>Clinical Form</th>
<th>Antigen</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Efficiency</th>
<th>Cutoff Titer (log2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG Acute and Chronic</td>
<td>Amastigote</td>
<td>0.938</td>
<td>0.952</td>
<td>0.946</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>0.871</td>
<td>0.882</td>
<td>0.877</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>0.804</td>
<td>0.974</td>
<td>0.897</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>IgM Acute</td>
<td>Amastigote</td>
<td>0.861</td>
<td>0.872</td>
<td>0.871</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>0.889</td>
<td>0.463</td>
<td>0.518</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>0.861</td>
<td>0.839</td>
<td>0.842</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>IgA Acute</td>
<td>Amastigote</td>
<td>0.611</td>
<td>0.913</td>
<td>0.868</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>0.472</td>
<td>0.778</td>
<td>0.733</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>0.194</td>
<td>0.662</td>
<td>0.593</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>IgA Chronic Digestive</td>
<td>Amastigote</td>
<td>0.923</td>
<td>0.913</td>
<td>0.914</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>0.192</td>
<td>0.778</td>
<td>0.712</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>0.038</td>
<td>0.862</td>
<td>0.592</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
Table 2, 3 and 4 present the reactivities for serum samples from patients in the several groups studied in relation to the established cutoffs for IgG, IgM and IgA IF tests, respectively.

In IgG IF test with epimastigote, poor results (37%) were obtained with serum samples from digestive forms of Chagas' disease. In acute chagasic infections, positivity was high for IgM IF test with any of the three studied antigens. Also in serum samples from indeterminate forms, positivities of 23%, 45% and 32% were seen for IgG IF test with amastigote, trypomastigote and epimastigote antigens, respectively.

In IgA IF test with amastigote, positivity was high in digestive form and in acute infection. However in indeterminate forms, positivity of 21% was observed, and in cardiac forms, 16%. Higher nonspecific reactivities are seen in IgG and IgM IF tests with trypomastigote and in IgA IF with trypanomastigote and epimastigote.

As illustrated in table 5, anti-amastigote IgG, IgM and IgA antibodies presented higher GMT in relation to anti-trypomastigote and anti-epimastigote. Titers of anti-amastigotes IgG antibodies ranged from 64 x 102 to 20 x 105; of IgM antibodies, from 12 x 104 to 20 x 106 and of IgA antibodies in sera either from acute or digestive forms, from 25 x 105 to 26 x 106.

**DISCUSSION**

In the present study, two aspects were investigated: the first dealing with T. cruzi antigens (amastigote, trypanomastigote and epimastigote) which might provide better diagnostic performance, in a comparative study by IF test, and the second, with immunological markers for dif-

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positivity in IF tests for IgG antibodies with amastigote, trypomastigote and epimastigote antigens in serum samples from chagasic (225) and nonchagasic patients (272)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N: of Serum</td>
</tr>
<tr>
<td>CHAGAS' DISEASE:</td>
</tr>
<tr>
<td>Acute:</td>
</tr>
<tr>
<td>36</td>
</tr>
<tr>
<td>32 (89%)</td>
</tr>
<tr>
<td>28 (78%)</td>
</tr>
<tr>
<td>21 (58%)</td>
</tr>
<tr>
<td>Chronic:</td>
</tr>
<tr>
<td>Indeterminate</td>
</tr>
<tr>
<td>128</td>
</tr>
<tr>
<td>119 (93%)</td>
</tr>
<tr>
<td>116 (91%)</td>
</tr>
<tr>
<td>120 (94%)</td>
</tr>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td>31</td>
</tr>
<tr>
<td>30 (97%)</td>
</tr>
<tr>
<td>26 (84%)</td>
</tr>
<tr>
<td>29 (94%)</td>
</tr>
<tr>
<td>Digestive</td>
</tr>
<tr>
<td>30</td>
</tr>
<tr>
<td>30 (100%)</td>
</tr>
<tr>
<td>26 (87%)</td>
</tr>
<tr>
<td>11 (37%)</td>
</tr>
<tr>
<td>OTHER DISEASE:</td>
</tr>
<tr>
<td>Acute rubella</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>2 (20%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Acute toxoplasmosis</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>4 (40%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Malaria</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>1 (5%)</td>
</tr>
<tr>
<td>3 (15%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Kala-azar</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>1 (10%)</td>
</tr>
<tr>
<td>2 (20%)</td>
</tr>
<tr>
<td>Mucocutaneous leishmaniasis</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>2 (17%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Syphilis</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>2 (20%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Connective tissue disease</td>
</tr>
<tr>
<td>32</td>
</tr>
<tr>
<td>3 (9%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Pemphigus foliaceus</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>3 (38%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>CLINICALLY HEALTHY:</td>
</tr>
<tr>
<td>Blood donors</td>
</tr>
<tr>
<td>60</td>
</tr>
<tr>
<td>4 (7%)</td>
</tr>
<tr>
<td>6 (10%)</td>
</tr>
<tr>
<td>0 (0%)</td>
</tr>
<tr>
<td>Individuals from endemic areas of Chagas' disease</td>
</tr>
<tr>
<td>100</td>
</tr>
<tr>
<td>5 (5%)</td>
</tr>
<tr>
<td>9 (9%)</td>
</tr>
<tr>
<td>5 (5%)</td>
</tr>
</tbody>
</table>

175
TABLE 3
Positivity in IF tests for IgM antibodies with amastigote, trypomastigote and epimastigote antigens in serum samples from chagasic (149) and nonchagasic patients (129)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>N of Serum</th>
<th>N: Positive Sera (%)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Amastigote</td>
<td>Trypomastigote</td>
<td>Epimastigote</td>
<td></td>
</tr>
<tr>
<td>CHAGAS’ DISEASE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute:</td>
<td>36</td>
<td>31 (86%)</td>
<td>32 (89%)</td>
<td>31 (86%)</td>
<td></td>
</tr>
<tr>
<td>Chronic:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indeterminate</td>
<td>56</td>
<td>13 (23%)</td>
<td>25 (45%)</td>
<td>18 (32%)</td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>31</td>
<td>0 (0%)</td>
<td>9 (29%)</td>
<td>4 (13%)</td>
<td></td>
</tr>
<tr>
<td>Digestive</td>
<td>25</td>
<td>2 (8%)</td>
<td>8 (31%)</td>
<td>3 (12%)</td>
<td></td>
</tr>
<tr>
<td>OTHER DISEASE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute rubella</td>
<td>10</td>
<td>0 (0%)</td>
<td>9 (90%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Acute toxoplasmosis</td>
<td>19</td>
<td>4 (21%)</td>
<td>12 (63%)</td>
<td>3 (16%)</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>10</td>
<td>1 (10%)</td>
<td>8 (80%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Kala-azar</td>
<td>10</td>
<td>0 (0%)</td>
<td>3 (30%)</td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>Muco-cutaneous</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>leishmaniasis</td>
<td>10</td>
<td>2 (20%)</td>
<td>10 (100%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Syphilis</td>
<td>10</td>
<td>1 (10%)</td>
<td>10 (100%)</td>
<td>5 (50%)</td>
<td></td>
</tr>
<tr>
<td>Connective tissue disease</td>
<td>10</td>
<td>0 (0%)</td>
<td>2 (20%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>CLINICALLY HEALTHY:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood donors</td>
<td>30</td>
<td>2 (7%)</td>
<td>17 (57%)</td>
<td>2 (7%)</td>
<td></td>
</tr>
<tr>
<td>Individuals from endemic areas of Chagas’ disease</td>
<td>20</td>
<td>6 (30%)</td>
<td>17 (85%)</td>
<td>3 (15%)</td>
<td></td>
</tr>
</tbody>
</table>

Different clinical forms of Chagas’ disease (acute and chronic indeterminate, cardiac and digestive forms).

Thus, higher diagnostic performance indexes were obtained for IgG, IgM and IgA IF tests with amastigote antigens, in the study of different clinical forms of Chagas’ disease, in relation to the tests with trypomastigote and epimastigote. Amastigote antigens as prepared here from T. cruzi infected mice were not evaluated before in serological tests for diagnostic purpose.

Cutoff titers vary according to the type of antigen and panel of sera selected from populations for the standardization of tests. Inasmuch as in this work many nonrelated infections were included, the cutoff titers are in general higher in comparison with those reported. Thus, the cutoff for IgG IF with amastigote stipulated here is higher than those reported for tests with amastigote from cell cultures and with amastigote of skeletal muscle sections from infected mouse with T. cruzi. Also, in the same test with trypomastigote and epimastigote, the titers taken as cutoffs are higher than those reported. Even in IgM IF test with epimastigote, the cutoff titer is slightly higher than that determined before. Nevertheless, in IgA IF with amastigote, the cutoff titer used is similar to that established in the previous work.

Titers of anti-amastigote IgG, IgM and IgA antibodies in sera from group of patients studied are also higher, as well as their GMT. In general, the anti-amastigote IgG antibody titers varied in similar range to the titers of anti-amastigote of skeletal muscle sections from infected mouse. These high reactivity of antibody to amastigote antigen was verified to be specific with
### TABLE 4

Positivity in IF tests for IgA antibodies with amastigote, trypomastigote and epimastigote antigens in serum samples from chagasic (149) and nonchagasic patients (120)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>N: of Serum</th>
<th>N: Positive Sera (%)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Amastigote</td>
<td>Trypomastigote</td>
<td>Epimastigote</td>
<td></td>
</tr>
<tr>
<td><strong>CHAGAS' DISEASE:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute:</td>
<td>36</td>
<td>22 (61%)</td>
<td>17 (47%)</td>
<td>7 (19%)</td>
<td></td>
</tr>
<tr>
<td>Chronic:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indeterminate</td>
<td>56</td>
<td>12 (21%)</td>
<td>7 (13%)</td>
<td>15 (27%)</td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>31</td>
<td>5 (16%)</td>
<td>1 (3%)</td>
<td>10 (32%)</td>
<td></td>
</tr>
<tr>
<td>Digestive</td>
<td>26</td>
<td>24 (92%)</td>
<td>5 (19%)</td>
<td>1 (4%)</td>
<td></td>
</tr>
<tr>
<td><strong>OTHER DISEASE:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute rubella</td>
<td>10</td>
<td>0 (0%)</td>
<td>2 (20%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Acute toxoplasmosis</td>
<td>10</td>
<td>0 (0%)</td>
<td>2 (20%)</td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>10</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Kala-azar</td>
<td>10</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>Mucoceutaneous leishmaniasis</td>
<td>10</td>
<td>0 (0%)</td>
<td>7 (70%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Syphilis</td>
<td>10</td>
<td>0 (0%)</td>
<td>9 (90%)</td>
<td>10 (100%)</td>
<td></td>
</tr>
<tr>
<td>Connective tissue disease</td>
<td>10</td>
<td>0 (0%)</td>
<td>3 (30%)</td>
<td>4 (40%)</td>
<td></td>
</tr>
<tr>
<td><strong>CLINICALLY HEALTHY:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood donors</td>
<td>30</td>
<td>0 (0%)</td>
<td>11 (37%)</td>
<td>26 (87%)</td>
<td></td>
</tr>
<tr>
<td>Individuals from endemic areas of Chagas' disease</td>
<td>20</td>
<td>1 (5%)</td>
<td>4 (20%)</td>
<td>3 (15%)</td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 5

Geometric mean titers (GMT) and standard deviations (sd), estimated for anti-amastigote, anti-trypomastigote and anti-epimastigote antibodies from patients with acute (A) and chronic indeterminate (CI), cardiac (CC) and digestive (CD) forms of Chagas' disease, in IF tests for IgG, IgM and IgA antibodies

<table>
<thead>
<tr>
<th>IF test</th>
<th>Antigen</th>
<th>Log&lt;sub&gt;10&lt;/sub&gt; GMT (sd)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Chagas's disease</td>
<td>Nonchagasic infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A</td>
<td>CI</td>
<td>CC</td>
<td>CD</td>
</tr>
<tr>
<td>IgG</td>
<td>Amastigote</td>
<td>11.3 (4.0)</td>
<td>11.4 (2.5)</td>
<td>11.1 (2.4)</td>
<td>11.9 (2.5)</td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>6.7 (2.8)</td>
<td>6.9 (1.9)</td>
<td>6.1 (2.0)</td>
<td>7.0 (2.2)</td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>4.9 (1.7)</td>
<td>7.2 (1.5)</td>
<td>6.8 (1.3)</td>
<td>4.0 (2.6)</td>
</tr>
<tr>
<td>IgM</td>
<td>Amastigote</td>
<td>12.6 (4.4)</td>
<td>6.2 (3.5)</td>
<td>4.5 (2.4)</td>
<td>5.7 (3.0)</td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>7.4 (2.7)</td>
<td>3.5 (2.9)</td>
<td>2.7 (3.1)</td>
<td>2.8 (2.7)</td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>7.2 (1.6)</td>
<td>3.3 (3.0)</td>
<td>2.2 (2.6)</td>
<td>2.7 (2.3)</td>
</tr>
<tr>
<td>IgA</td>
<td>Amastigote</td>
<td>10.4 (4.1)</td>
<td>7.3 (2.7)</td>
<td>7.7 (1.9)</td>
<td>12.6 (3.8)</td>
</tr>
<tr>
<td></td>
<td>Trypomastigote</td>
<td>3.2 (3.0)</td>
<td>1.2 (1.6)</td>
<td>0.7 (0.5)</td>
<td>1.3 (2.0)</td>
</tr>
<tr>
<td></td>
<td>Epimastigote</td>
<td>1.2 (1.8)</td>
<td>1.2 (1.6)</td>
<td>1.4 (1.8)</td>
<td>0.5 (0.1)</td>
</tr>
</tbody>
</table>
no interference of mouse tissue components in our previous work. In IgG IF test with amastigote antigens, positivities found for different forms of Chagas' disease are all higher, whereas in test with conventional epimastigote, the positivity was low only for digestive form of Chagas' disease. Hence misleading diagnoses of Chagas' disease among patients with digestive impairment seem to be frequent in endemic areas.

The sensitivity of IgG IF test with trypomastigotes was lower than that reported by SADUN, but its specificity lies within the values obtained by some investigators.

Positive correlation between the acute form of Chagas' disease and IgM antibodies to amastigote, to trypomastigote and to epimastigote were found, and these findings were expected, since anti-epimastigote IgM antibodies were detected previously in acute infections. The relevant finding however was the detection of IgA antibodies to amastigote antigens, in analogous way to those non-related acute infections, in which this class of specific antibodies are demonstrated to have pathogenic significance and diagnostic value. Positivities in IgM and IgA IF tests should be improved in acute chagasic infections seeing that in several negative cases, the antibodies are possibly present in low titers, similarly to IgM antibodies in acute toxoplasmosis. Therefore, we are trying now to remove IgG antibodies which might be interfering, by mean of well known procedures to enhance the reactivities of IgM and IgA antibodies in IF tests.

Trypomastigotes rather than epimastigotes gave higher nonspecific results in IgM and in IgA IF tests, possibly by ubiquitous antigenic determinants common to Treponema pallidum, Leishmania sp amastigotes, and other microorganisms, but absent from T. cruzi amastigotes.

As verified previously, anti-amastigote IgA antibodies correlated closely with chronic digestive forms of Chagas' disease, and these might be an early serological signal of mucosa lesions when revealed in chronic disease, in the absence from IgM antibodies. In 12 patients with indeterminate forms, IgA antibodies were found, and 7 of these had also IgM antibodies. It is possible they were still in acute phase of infection with no defined symptoms and, due to their positivity in conventional serology, were considered as indeterminate forms. These 12 cases were all from Mambai (GO), an endemic area for Chagas' disease, where light infections can not be ruled out. As to the remainders 5, as well as 5 from cardiac forms in which IgA antibodies were found, with no IgM, have to be closely monitored to investigate whether the disease will progress with the onset of digestive disturbances.

In brief, the amastigote proved to be more sensitive antigen to detect IgG, IgM and IgA antibodies from different forms of Chagas' disease and this would be helpful for screening chagasic infections in blood banks. As to the immunological markers, IgA antibodies suggest to be correlated with acute infections along with IgM antibodies.

Amastigote as here obtained is more convenient and less costly for developing countries, since in most laboratories which produces their own antigens has animal quarter facilities rather than specialized personnel and substruction for cell culture, or then equipment such as cryostat to provide tissue sections of infected animal with T. cruzi as antigenic substrate.

RESUMO

Doença de Chagas: anticorpos IgG, IgM e IgA contra antígenos de amastigota, tripanastigota e epimastigota de T. cruzi em formas agudas e em diferentes formas crônicas da doença.

Com o intuito de se aperfeiçoar o diagnóstico sorológico das diferentes formas clínicas da doença de Chagas, foram estudados antígenos de formas amastigota e tripanastigota, obtidas de camundongos imunossuprimidos infectados com cepa Y de T. cruzi, em comparação com o de epimastigota convencionalmente utilizado. Um total de 506 amostras de soro de pacientes chagásicos com formas aguda e crónica (indeterminada, cardíaca e digestiva), de indivíduos com infecções não relacionadas e de indivíduos sadios foi analisado por reação de imunofluorescência, para detecção de anticorpos IgG, IgM e IgA. O antígeno de amastigota apresentou os


ACKNOWLEDGEMENTS

This work was supported by Conselho de Desenvolvimento Científico e Tecnológico (CNPq — PIDE VI), and by Fundação de Amparo à Pesquisa do Estado de São Paulo.

We thank Rosely dos Santos Malafonte for technical assistance and Maria Inês Cardillo Serafim for helping in the preparation of the manuscript.

REFERENCES


Received para publicação em 25/9/1989.